A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This multicenter, randomized study will evaluate the efficacy and safety of apatinib compared
to docetaxel treatment in patients with advanced gastric cancer. At the start of the trial,
patients will be randomized to one treatment arm: Arm A: apatinib 850mg qd every 3 weeks; Arm
B: docetaxel 60mg/m2 every 3 weeks. Tumor assessment will be done every 8 weeks according to
RECIST 1.1. The primary endpoint is progression free survival (PFS).